ライフサイエンスコーパス: company

1 stellas Pharma Inc, Medivation LLC (a Pfizer Company).

2 o facilitate this approach (EndotorchTM Wolf Company).

3 ly owned subsidiary of Takeda Pharmaceutical Company.

4 , a wholly owned subsidiary of Eli Lilly and Company.

5 tion, and Juno Therapeutics, Inc., a Celgene Company.

6 idges were left by the pipeline construction company.

7 ny and category of disclosure and matches on company.

8 Juno Therapeutics, a Bristol-Myers Squibb Company.

9 most PE firms developing multistate platform companies.

10 PA) will reach shadow health records in many companies.

11 s than the noninventor employees in the same companies.

12 transgenic traits developed by biotechnology companies.

13 representing several dozen institutions and companies.

14 fluoropolymer market, as well as to end-user companies.

15 eidentified medical-record data by insurance companies.

16 by medical doctors and 2% by pharmaceutical companies.

17 and challenging enterprise of pharmaceutical companies.

18 ther that this is driven by small indigenous companies.

19 nd few are sponsored by large pharmaceutical companies.

20 63 (18%) products, developed by 47 different companies.

21 and funded by African institutes and private companies.

22 ether with pharmaceutical venture capitalist companies.

23 leted studies sponsored by 13 pharmaceutical companies.

24 nder investigation in various pharmaceutical companies.

25 hrough collaborations with 18 pharmaceutical companies.

26 rganisms, fostering a new crop of anti-aging companies.

27 to raw genomic data using direct-to-consumer companies.

28 , and donations of drugs from pharmaceutical companies.

29 nvestors, which is especially apparent among companies.

30 ons, and that lower enforcement attracts all companies.

31 ograms have voluntarily been put in place by companies.

32 ntists hoping to partner with pharmaceutical companies.

33 on, now part of the GlaxoSmithKline group of companies.

34 and 7 are currently marketed by 1 of 3 large companies.

35 vailable on the website hitilab.org/pages/ai-companies.

36 processing facilities and large meatpacking companies.

37 ble press releases from PE firms or platform companies.

38 rists were acquired by 29 PE-backed platform companies.

39 d the associated transfer of know-how across companies.

40 tions and the performance of publicly traded companies.

41 Large pharmaceutical vs nonpharmaceutical companies.

42 of TSMC (Taiwan Semiconductor Manufacturing Company) 12 nm fin field-effect transistor (FinFET), 28

43 nt datasets, including the personal genetics company 23andMe, Inc. and whole-genome sequencing data.

44 arch participants from the personal genetics company 23andMe, Inc., and 431,094 UK Biobank participan

45 In collaboration with the genetics company 23andMe, we performed 10 genome-wide association

46 6 product carbon footprints (PCFs), from 145 companies, 30 industries, and 28 countries.

47 Products from company A were traced and recalled from >6000 food estab

48 nd that, among refugees employed by the same company, a high proportion share nationality, ethnicity,

49 ong employees of a large US warehouse retail company, a workplace wellness program resulted in signif

50 health care professionals by pharmaceutical companies accounted for most promotional spending and in

51 lobal medical evidence software and services company, across PubMed and EMBASE from 1966 to 2015 usin

52 Professional surveyors from 16 oil and gas companies and 8 regulatory agencies participated, comple

53 r this dataset by embedding the positions of companies and directors in a latent space.

54 which prevents optimal connectivity between companies and end-users.

55 1997, 103 financial settlements between drug companies and federal and state governments resulted in

56 iduals prefer to keep their connections with companies and funds.

57 , we combined data from three pharmaceutical companies and generated ADMET rules, avoiding the need t

58 Companies and governments with sustainability commitment

59 rly development (R&D) is executed in biotech companies and large pharmaceutical organizations.

60 , it will be of considerable use to start-up companies and other commercial entities looking to enter

61 Pharmaceutical companies and other trial sponsors must submit certain t

62 atives analysis would advance the ability of companies and regulators to select alternatives to harmf

63 The use of R. toruloides by companies and research groups has exponentially increase

64 acilitating collaboration between diagnostic companies and the ARLG Master Protocol for Evaluating Mu

65 poral bipartite network of the leading Irish companies and their directors from 2003 to 2013, encompa

66 g nodule abundance is of interest for mining companies and to monitor potential environmental impact.

67 ONO Pharmaceutical Company and Bristol-Myers Squibb.

68 sures to ASCO and payments in OP was 16% for company and category matching and 24% for matching on th

69 e calculated on the basis of matches on both company and category of disclosure and matches on compan

70 ibe how partnering works in a pharmaceutical company and offer advice on how to make a successful tra

71 tfolio manager in a larger biopharmaceutical company and the skills from academic research I leverage

72 lated from further samples taken within this company and within companies in its distribution chain.

73 ere initially developed by small to midsized companies, and 7 are currently marketed by 1 of 3 large

74 y sensitive to the presence of a few outlier companies, and confirm that nearly all biotech companies

75 Manufacturers, companies, and health care professionals and organizatio

76 set of requirements that investigators, drug companies, and journals should consider to optimize thei

77 -setting bodies, governments, pharmaceutical companies, and philanthropic organizations.

78 across many different contexts: Governments, companies, and political parties use persuasive appeals

79 this type will help planners, transportation companies, and society at large to shape a sustainable p

80 they are currently used within MLPDS member companies, and the outlook for this field.

81 f drug licensing agencies and pharmaceutical companies, and trial registries.

82 Mort database and other sources at the town, company, and individual level to assess the relation bet

83 Pharmacyclics LLC, an AbbVie Company, and Janssen Research and Development.

84 Eli Lilly and Company, and Merck and Co.

85 While many companies are active in the field, scientists engaged in

86 During this period, pharmaceutical companies are allowed to set their list price as high as

87 A plurality of companies are focused on nodule detection at chest CT an

88 Other companies are following suit, harnessing iPSCs' self-ren

89 mpanies, and confirm that nearly all biotech companies are loss-making enterprises, exhibiting high s

90 as well as biotechnology and pharmaceutical companies are on the verge of bringing these therapies i

91 d insufficient investments by pharmaceutical companies are some of the clear reasons behind market fa

92 d is being widely accepted by pharmaceutical companies as a drug development tool.

93 since ceria was first employed by Ford Motor Company as an oxygen storage component in car converters

94 ed collaboratively and constructively within companies at an early stage to anticipate consequences a

95 , and firms with different financial risk in company balance sheets.

96 rs of cooperating statutory health insurance companies between 25 and 50 years of age living in a mod

97 setts) or General Electric (General Electric Company, Boston, Massachusetts) FFDM machines between 20

98 ties offered by gold mining and agricultural companies but continue to depend on forests for house co

99 gnificantly greater than other large, public companies, but the difference was less pronounced when c

100 Clinicians, patients, and pharmaceutical companies can report adverse drug reactions (ADRs) to ph

101 o hinder the spread of resistance, but small companies cannot survive on revenues that do not cover o

102 siting and permitting process so oil and gas companies, communities, and states can identify cost-eff

103 percent were developed by medical technology companies compared to 18% by medical doctors and 2% by p

104 environmental authorities do not ensure that companies comply with the legislation.

105 Three platform companies, comprising 60% of platforms formed before 201

106 Furthermore, larger pharmaceutical companies continue to abandon the field, and smaller com

107 ibiotic innovation is in serious jeopardy as companies continue to abandon the market due to a lack o

108 Larger companies contribute more to these patterns.

109 Multiple pharmaceutical companies currently test CDK4/6 inhibitors in combinatio

110 s from a large commercial genomic sequencing company database was published, followed by large-scale

111 ol and Prevention, and Becton, Dickinson and Company developed a public-private partnership (PPP).

112 Support from major biopharmaceutical companies, development of hydroponic production systems,

113 This is because construction/concessionary companies do not consider the environmental impact of co

114 We contacted pharmaceutical companies, drug regulatory authorities, and study invest

115 nse interest by academics and pharmaceutical companies due to their potential to hit currently "undru

116 When these companies either go bankrupt or move onto other therapeu

117 lecules; there are at least a few reports of companies employing in silico synthetic planning into th

118 ving enzyme 1 (BACE-1), with many big pharma companies expending great resources in the search for BA

119 s continue to abandon the field, and smaller companies face financial difficulties as a consequence.

120 panies for lower prices by offering the drug company favorable formulary placement and fewer utilizat

121 Pharmaceutical companies find drug development programs increasingly co

122 financial penalties levied on pharmaceutical companies for illegal activities by type of activity and

123 harmacy benefit managers negotiate with drug companies for lower prices by offering the drug company

124 o basic research laboratories and diagnostic companies for research and development, facilitating col

125 the commercial devices and kits developed by companies for the detection of SARS-CoV-2.

126 ured variously as patents filed or licensed, companies founded, number of papers and books published,

127 blood culture bottles (Becton, Dickinson and Company, Franklin Lakes, NJ) inoculated with 27 differen

128 k the performance of 1,066 biopharmaceutical companies from 1930 to 2015-the most comprehensive finan

129 measures are described as cumulative for all companies from 2000 to 2018 or annual profit as a fracti

130 r accuracy, determine whether pharmaceutical companies from which the authors received payments manuf

131 dentified by the Ophthalmic Mutual Insurance Company from closed case files and by the New York State

132 belonging to a large, national managed care company from January 1, 2005, to December 31, 2012.

133 ance plans at a large US managed health care company from January 1, 2008, through February 29, 2016.

134 rs among shareholders, who are classified as companies, funds and individuals.

135 searchers, food and nutrition professionals, companies, government officials, and individuals working

136 significantly greater than those of S&P 500 companies (gross profit margin: 76.5% vs 37.4%; differen

137 duce emissions varied depending on whether a company had reported a PCF's breakdown to life cycle sta

138 d, via the 204 exporting and 3,383 importing companies handling that trade, and finally to 152 import

139 n natural products from major pharmaceutical companies has decreased even as genomics has uncovered t

140 ed in patent records by major pharmaceutical companies has dramatically decreased, which may lead to

141 In contrast, since 2000, pharmaceutical companies have become increasingly profitable, with risk

142 Several academic groups and pharmaceutical companies have been developing a series of non-steroidal

143 Pharmaceutical companies have considerable flexibility in how they pric

144 Additionally, private equity-backed platform companies have developed both regionally focused and mul

145 protein surface, and several pharmaceutical companies have developed compounds and performed clinica

146 Many pharmaceutical companies have expended huge efforts on both stimulation

147 During the past 60 min, oil companies have extracted 6 trillion liters of oil from t

148 Environmental scientists and companies have learned from the experiences of the past;

149 Branded drug companies have patents and market exclusivity periods in

150 chemistry groups within large pharmaceutical companies have realized growth in the number of women, a

151 excitement in this field has grown, several companies have recently initiated testing of direct NLRP

152 In the past decade, pharmaceutical companies have reduced their natural product discovery p

153 Transnational tobacco companies have sought to undermine tobacco tax policy by

154 hat all therapies-often drugs from different companies-have to be available at the same time when the

155 eased rapidly since 2012, with some platform companies having already been sold or recapitalized to n

156 itium data published by Tokyo Electric Power Company Holdings (TEPCO) (17,000 points), the postulated

157 nfluenced project design and relations among companies, host governments, and locally impacted commun

158 a community, alleles at a genetic locus, and companies in a market are characterized by competition (

159 The interest of tobacco companies in genetic information as well as the success

160 samples taken within this company and within companies in its distribution chain.

161 engage Wall Street and large pharmaceutical companies in radiopharmaceutical opportunities.

162 from 4 machinery and equipment manufacturing companies in Taichung, Taiwan, was followed from 1973 to

163 has doubled, the output from 23 large pharma companies in the past decade has dropped significantly.

164 f 35 large pharmaceutical companies with 357 companies in the S&P 500 Index from 2000 to 2018 using i

165 ducted in 2011 and 2012 by a private housing company in about 1,800 apartments.

166 zed between 1946 and 2015 from a single seed company in multiple N fertilizer treatments, we demonstr

167 llions of data points) from the largest taxi company in Singapore suggests that there is an explicit

168 8,906 users of Airbnb, a leading hospitality company in the sharing economy.

169 The approach described has been used at our company in various stages of discovery since 2001.

170 Additionally, pharmaceutical companies, in light of promising early-stage results, ha

171 Pharmaceutical companies increased DTC marketing about diseases treated

172 Do campaign contributions from oil and gas companies influence legislators to vote against the envi

173 ptions of tobacco use, peer use, and tobacco-company influences.

174 Physicians who received company information about the unapproved use of Vascepa

175 This article describes why pharmaceutical companies invest in antimicrobial stewardship, outlines

176 to vote against the environment, or do these companies invest in legislators that have a proven antie

177 of the very large exchange of knowledge, all companies involved synergistically gained approximately

178 2009, primarily led by small pharmaceutical company involvement.

179 standing the profitability of pharmaceutical companies is essential to formulating evidence-based pol

180 The performance of all biopharmaceutical companies is subject not only to factors arising from th

181 exchange on a global level, sharing-economy companies leverage interpersonal trust between their mem

182 ly owned subsidiary of Takeda Pharmacuetical Company Limited, and National Institutes of Health Natio

183 (22) and "unspecified" (12); however, other companies listed more ocular-specific routes such as int

184 Companies make decisions about the safety of some food c

185 nd nonphysician practitioners working for US companies marketing unproven stem cell procedures.

186 xcess of the $50000 net and/or $20000 single-company maximums stipulated by NCCN.

187 on the profitability of large pharmaceutical companies may be relevant to formulating evidence-based

188 ising MIT and 13 chemical and pharmaceutical company members.

189 07 with US sales reported by publicly traded companies (n = 602 drugs).

190 ompared with that among employees from other companies not offered the tool (n=295,983) in the year b

191 ed patient is set by the patient's insurance company-not the manufacturer, distributor, or pharmacy-a

192 organized a workshop with the support of The Company of Biologists to debate the current state of kno

193 is Spotlight summarizes conclusions from The Company of Biologists Workshop 'Understanding Human Birt

194 tion gathered in late September 2016 for The Company of Biologists' second 'From Stem Cells to Human

195 regulation of development' organized by The Company of Biologists.

196 Among employees at 2 large companies, offering a price transparency tool was not as

197 atching and 24% for matching on the basis of company only.

198 violations relies largely on complaints from company outsiders, which may explain why most off-label

199 We analyze data from 805 companies over 32 y to explore how new sexual harassment

200 nstrained by the location of high-efficiency company-owned mills.

201 to assess the relation between the dominant company ownership of a town and mortality.

202 thal gene has been developed by a commercial company, Oxitec Ltd.

203 Financing rounds of platform companies paralleled temporal acquisition trends.

204 cation sequence was generated by an external company; patients were randomly assigned (1:1:1) to rece

205 y other parties, including biopharmaceutical companies, payors, clinical researchers, providers, and

206 ional Mental Health Institute, Eli Lilly and Company, Pfizer Pharmaceuticals, and the Edwin S Webster

207 d reward of investments in biopharmaceutical companies poses a challenge to those interested in fundi

208 7 knock-out mice generated by pharmaceutical companies possess certain splice variants, which evade i

209 been reinvigorated, most recently by private companies proposing to utilize lateral drilling technolo

210 te disclosure statement accuracy, detail the companies providing payments, and evaluate Administrativ

211 Many pharmaceutical companies recognise the advantages of revealing some pro

212 e (low, medium, and high) were obtained from company records.

213 zing the issues, the hope is that commercial companies, regulatory agencies, and professional societi

214 From 2000 to 2018, 35 large pharmaceutical companies reported cumulative revenue of $11.5 trillion,

215 t income of $1.9 trillion, while 357 S&P 500 companies reported cumulative revenue of $130.5 trillion

216 to determine sources of discordance between company-reported and self-reported financial relationshi

217 antial discordance between self-reported and company-reported financial relationships for authors who

218 Company-reported payments from the Open Payments databas

219 Net prices were estimated by compiling company-reported sales for each product and number of un

220 pany size and year and when considering only companies reporting research and development expense (gr

221 g patterns of consumer countries and trading companies result in substantially different impacts on e

222 such as species abundances in ecosystems, or company revenues in economic networks.

223 Manufacturing companies routinely use copper fibers for blanket fabric

224 d on shared data compared to both individual companies' rules and rules published in the literature.

225 order a 23andMe test after reading about the company's carrier screening test and the new BRCA1/BRCA2

226 upstream in the supply chain, 23% during the company's direct operations, and 32% downstream.

227 ted with increased prescribing of the paying company's drug, increased prescribing costs, and increas

228 he Mexican urban population from The Nielsen Company's Mexico Consumer Panel Services (CPS).

229 These discoveries are then included in a company's pipeline and help bring novel treatments to pa

230 We test whether companies seek out less-regulated forest areas for new a

231 pose significant health care problems, drug companies seldom develop drugs for orphan diseases due t

232 enefits of these drugs, and health insurance companies should provide reasonable coverage for their u

233 smaller in regression models controlling for company size and year and when considering only companie

234 ference was less pronounced when considering company size, year, or research and development expense.

235 ately insured individuals in 69 self-insured companies spanning diverse industries.

236 All 40 companies specified sources of cells, which included aut

237 Company-sponsored (Genentech or Novartis) studies in DME

238 When pharmaceutical company sponsorship ended at 8.4 years of median follow-

239 xecutive officers, field surveys in large US companies, student leader nominations and elections, and

240 rol subjects) and the Janssen-Brain Resource Company study (94 patients and 100 control subjects).

241 professional drug promotional materials that companies submitted for FDA review increased from 34 182

242 If even one company succeeds, however, the impact will be huge.

243 Numerous companies, such as Asahi Glass, Solvay Specialty Polymer

244 contributions they receive from oil and gas companies supporting their reelection.

245 The study included companies that are U.S. based, participate in direct-to-

246 line network, we systematically identify the companies that maximize (and those that less compromise)

247 turn is dependent on the breeding designs of companies that supply inbred mice to researchers.

248 itro in 1961, has become a focus for biotech companies that target it to ameliorate a variety of huma

249 restation regulations attract investments by companies that tend to clear more forest, mostly cattle

250 is article initially published, we listed 13 companies that were developing phage therapies a decade

251 Companies that would submit to this process would earn t

252 , a large, globally operating pharmaceutical company that develops and markets both human and veterin

253 tive agent of skin changes in employees of a company that produced herbal medicines.

254 July and August of 2012 while working for a company that produced herbal medicines.

255 portive supervision, using Magpi software (a company that provides service to collect data using mobi

256 sis Critical Control Point system by seafood companies, the number of seafood-related foodborne illne

257 rest from academic groups and pharmaceutical companies, there are currently few approved medicines ta

258 lopment, as it would pressure pharmaceutical companies to become more innovative and avoid the develo

259 ould help consumers, policy makers, and food companies to better understand the multiple health and e

260 We have used data reported by companies to CDP for public disclosure to build a databa

261 led global food color manufacturers and food companies to dramatically increase the development and u

262 ary incentives for pharmaceutical and device companies to generate comparative data on drugs and devi

263 ely used in both academia and pharmaceutical companies to generate small-molecule protein inhibitors

264 test development, in particular with vaccine companies to identify novel diagnostic targets; by creat

265 oy the marketing practices of pharmaceutical companies to improve clinical practice.

266 tive market models are needed to incentivize companies to invest in developing new antibacterial drug

267 tations make it difficult for pharmaceutical companies to obtain full dissolution profiles for drug p

268 cess Mass Intensity (PMI) data from multiple companies to provide preliminary baseline metrics for cu

269 ), a commercially available credit reporting company, to construct residential histories for particip

270 A consortium of biotech companies, together with the Massachusetts Institute of

271 Based on interviews with 82 companies totaling 2.5 Mha of properties, we show that,

272 Many companies use life cycle assessment (LCA) to evaluate th

273 Every year pharmaceutical companies use significant resources to mitigate aggregat

274 onsent was not obtained and a pharmaceutical company used data for marketing (weighted mean appropria

275 (November 2016-June 2019), then narrowed to companies using deep learning for imaging analysis and d

276 the market overview, a list of radiology AI companies was aggregated from the Radiological Society o

277 ential profit margin favoring pharmaceutical companies was evidence of greater profitability.

278 8, the profitability of large pharmaceutical companies was significantly greater than other large, pu

279 d-based Internet search, content analysis of company websites was utilized to identify, document, and

280 Food and Drug Administration and company websites were searched from 1 January through 31

281 The top 15 companies were all pharmaceutical manufacturers and paid

282 A total of 119 software offerings from 55 companies were identified.

283 Nineteen companies were ruled in breach more than once, and ten c

284 were ruled in breach more than once, and ten companies were ruled in breach three or more times over

285 dian annual profit margins of pharmaceutical companies were significantly greater than those of S&P 5

286 In 1973, the Velsicol Chemical Company, which manufactured FireMaster, a brominated fla

287 The nodes of this network represent companies, while the links model the flow of employees a

288 he annual profits of 35 large pharmaceutical companies with 357 companies in the S&P 500 Index from 2

289 Forty companies with 76 clinics use "cell therapy" to treat oc

290 fendants accused of white-collar crimes, and companies with chief executive officers (CEOs) or chief

291 try by choosing to purchase from sustainable companies with environmentally friendly products.

292 Authors received payments from companies with products directly related to the guidelin

293 Individuals who work for a company with a primary financial dependency on drug sale

294 ons that also contain an alkali metal but in company with another metal.

295 ase in biliary cholesterol concentrations in company with hepatic hyposecretion of biliary bile salts

296 s the positioning of Litopterna (possibly in company with other SANU groups) as a separate order with

297 and Sandia National Laboratories (a private company with UAS research experience).

298 nalysis and analysed ownership data from 262 companies within these towns.

299 s by many research groups and pharmaceutical companies worldwide.

300 or distinguishing biotech and pharmaceutical companies yields a dynamic, more accurate classification